Effectiveness of antimalarial drug combinations in treating concomitant urogenital schistosomiasis in malaria patients in Lambaréné, Gabon: A non-randomised event-monitoring study.

Abstract

BACKGROUND:

Urogenital schistosomiasis is prevalent in many malaria endemic regions of sub-Saharan Africa and can lead to long-term health consequences if untreated. Antimalarial drugs used to treat uncomplicated malaria have shown to exert some activity against Schistosoma haematobium. Here, we explore the efficacy on concomitant urogenital schistosomiasis of first-line recommended artemisinin-based combination therapies (ACTs) and investigational second-generation ACTs when administered for the treatment of uncomplicated malaria in Gabon.

METHODS:

Microscopic determination of urogenital schistosomiasis was performed from urine samples collected from patients with confirmed uncomplicated malaria. Egg excretion reduction rate and cure rate were determined at 4-weeks and 6-weeks post-treatment with either artesunate-pyronaridine, artemether-lumefantrine, artesunate-amodiaquine or artefenomel-ferroquine.

RESULTS:

Fifty-two (16%) out of 322 malaria patients were co-infected with urogenital schistosomiasis and were treated with antimalarial drug combinations. Schistosoma haematobium egg excretion rates showed a median reduction of 100% (interquartile range (IQR), 17% to 100%) and 65% (IQR, -133% to 100%) at 4-weeks and 6-weeks post-treatment, respectively, in the artesunate-pyronaridine group (n = 20) compared to 35% (IQR, -250% to 70%) and 65% (IQR, -65% to 79%) in the artemether-lumefantrine group (n = 18). Artesunate-amodiaquine (n = 2) and artefenomel-ferroquine combination (n = 3) were not able to reduce the rate of eggs excreted in this limited number of patients. In addition, cure rates were 56% and 37% at 4- and 6-weeks post-treatment, respectively, with artesunate-pyronaridine and no cases of cure were observed for the other antimalarial combinations.

CONCLUSIONS:

Antimalarial treatments with artesunate-pyronaridine and artemether-lumefantrine reduced the excretion of S. haematobium eggs, comforting the hypothesis that antimalarial drugs could play a role in the control of schistosomiasis.

TRIAL REGISTRATION:

This trial is registered with clinicaltrials.gov, under the Identifier NCT04264130.

• Authors: Rella Zoleko-Manego, Dearie G Okwu, Christian Handrich, Lia B Dimessa-Mbadinga, Malick A Akinosho, Wilfrid F Ndzebe-Ndoumba, Saskia D Davi, Daniel Stelzl, Luzia Veletzky, Andrea Kreidenweiss, Tamara Nordmann, Ayola A Adegnika, Bertrand Lell, Peter G Kremsner, Michael Ramharter, Ghyslain Mombo-Ngoma
• Journal: PLoS neglected tropical diseases (PLoS Negl Trop Dis) Vol. 16 Issue 10 Pg. e0010899 (10 2022) ISSN: 1935-2735 [Electronic] United States
• PMID: 36315579 (Publication Type: Clinical Trial, Journal Article)
• Copyright: Copyright: © 2022 Zoleko-Manego et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Chemical References

• Amodiaquine
• Antimalarials
• artefenomel
• Artemether
• Artemether, Lumefantrine Drug Combination
• Artesunate
• Drug Combinations
• Ethanolamines
• ferroquine

Topics

• Humans
• Amodiaquine (therapeutic use)
• Antimalarials (therapeutic use)
• Artemether
• Artemether, Lumefantrine Drug Combination (therapeutic use)
• Artesunate (therapeutic use)
• Drug Combinations
• Ethanolamines (therapeutic use)
• Gabon (epidemiology)
• Malaria (drug therapy)
• Malaria, Falciparum (complications, drug therapy)
• Schistosomiasis haematobia (complications, drug therapy)